Check-Cap (NASDAQ:CHEK) Now covered by StockNews.com

StockNews.com initiated coverage of the stock of Check-Cap (NASDAQ:CHEK – Free Report) in a research report published on Thursday. The firm issued a sell rating on the medical research company’s stock.

Check stock by 6.0%

Shares of Check-Cap stock opened at $1.93 on Thursday. The stock has a market cap of $11.29 million, a P/E ratio of -0.64 and a beta of 0.40. Check-Cap has a 12-month low of $1.78 and a 12-month high of $4.63. The company’s 50-day moving average is $1.97 and its 200-day moving average is $2.15.

About Check-Cap

(Get a free report)

Check-Cap Ltd., a clinical-stage medical diagnostics company, is engaged in the development of a capsule-based screening technology that uses ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities . in Israel. Its C-Scan system consists of the C-Scan Cap, an X-ray scanning capsule for detecting suspected polyps; C-Scan Track, a single-use system attached to the patient’s back via biocompatible adhesive patches; and C-Scan View software, a client/server based application that allows download of procedure data from C-Scan Track, data analysis and report generation.

Recommended articles

Receive daily Check-Cap news and ratings – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Check-Cap and related companies with MarketBeat.com’s FREE daily email newsletter.